Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-18
2011-01-18
Chu, Yong (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252160, C514S217060, C514S383000, C544S253000, C548S265200, C548S266200, C548S266400
Reexamination Certificate
active
07872000
ABSTRACT:
Bicyclic aryl substituted triazoles or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
REFERENCES:
patent: 3813400 (1974-05-01), Boyle et al.
patent: 2004/0077699 (2004-04-01), Lin et al.
patent: 2004/0186288 (2004-09-01), Kruger et al.
patent: 2004/0214817 (2004-10-01), Pierce et al.
patent: 2005/0118604 (2005-06-01), Lorens et al.
patent: 2006/0293256 (2006-12-01), Yamada et al.
patent: 2007/0213375 (2007-09-01), Singh et al.
patent: 2008/0176847 (2008-07-01), Goff et al.
patent: 2008/0182862 (2008-07-01), Ding et al.
patent: 2008/0188455 (2008-08-01), Goff et al.
patent: 2008/0188474 (2008-08-01), Goff et al.
patent: 2009/0111816 (2009-04-01), Singh et al.
patent: 0 710 654 (1996-05-01), None
patent: WO 01/09106 (2001-02-01), None
patent: WO 02/057240 (2002-07-01), None
patent: WO 02/094814 (2002-11-01), None
patent: WO 03/027275 (2003-04-01), None
patent: WO 03/093344 (2003-11-01), None
patent: WO 2004/017997 (2004-03-01), None
patent: WO 2004/039955 (2004-05-01), None
patent: WO 2004/046120 (2004-06-01), None
patent: WO 2005/013982 (2005-02-01), None
patent: WO 2005/077922 (2005-08-01), None
patent: WO 2006/034116 (2006-03-01), None
patent: WO 2006/047256 (2006-05-01), None
patent: WO 2007/030680 (2007-03-01), None
patent: WO 2008/157131 (2008-12-01), None
STN—11966585A—11202009.
Agrafiotis et al., “SAR Maps: A New SAR Visualization Technique for Medicinal Chemists,”J. Med. Chem. 50(24): 5926-5937, 2007.
Alexander et al., “Human Parathyroid Hormone 1-34 Reverses Bone Loss in Ovariectomized Mice,”Journal of Bone and Mineral Research 16(9): 1665-1673, 2001.
Angelillo-Scherrer et al., “Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy,”Journal of Clinical Investigation 115(2): 237-246, Feb. 2005.
Bora et al., “Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration,”Proc. Natl. Acad. Sci U.S.A. 100(5): 2679-2684, Mar. 4, 2003.
Brewster et al., “Ro 32/3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis,”Arthritis&Rheumatism 41(9): 1639-1644, Sep. 1998.
Fujioka et al., “Equol, a Metabolite of Daidzein, Inhibits Bone Loss in Ovariectomized Mice,”Journal of Nutrition 134: 2623-2627, 2004.
Holland et al., “Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation,”Cancer Res. 65(20): 9294-9303, Oct. 15, 2005.
Holland et al., “Requirement for the Receptor Tyrosine Kinase Axl in Angiogenesis and Tumor Growth”, 7th Annual Symposium on Anti-Angiogenic Agents, Feb. 10-13, 2005, San Diego, California, 1 page.
Kadoya et al., “Role of calpain in hydrogen peroxide induced cataract,”Current Eye Research 12(4): 341-346, 1993.
Katritzky et al., “Syntheses of 5-(2-arylazenyl)-1,2,4-triazoles and 2-amino-5-aryl-l,3,4-oxadiazoles,”ARKIVOC 6: 82-90, 2002.
Kim et al., “Novel Oral Formulation of Paclitaxel Inhibits Neointimal Hyperplasia in a Rat Carotid Artery Injury Model,”Circulation 109: 1558-1563, Mar. 8, 2004.
Kurzer and Douraghi-Zadeh, “Heterocyclic Compounds from Urea Derivatives. Part VI. Synthesis and Cyclisation of 1-Amino-3-(NN'-diarylamidino)guanidines and Some Analogues,”J. Chem. Soc.932-937, 1965.
Lebovic et al., “Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis,”Fertility and Sterility 82(Suppl 3): 1008-1013, Oct. 2004.
Nakashima et al., “ApoE-Deficient Mice Develop Lesions of All Phases of Atherosclerosis Throughout the Arterial Tree,”Arterioscler. Thromb. Vasc. Biol. 14(1): 133-140, Jan. 1994.
Nickoloff et al., “Severe Combined Immunodeficiency Mouse and Human Psoriatic Skin Chimeras. Validation of a New Animal Model,”American Journal of Pathology 146(3): 580-588, Mar. 1995.
Peesapati and Venkata, “Synthesis and antimicrobial activity of new triazolo / tetrazolo-pyridazine [6,7] benzocycloheptenes,”Indian Journal of Chemistry 41B: 839-844, Apr. 2002.
Phadke et al., “Evaluation of the Effects of Various Anti-Arthritic Drugs on Type II Collagen-Induced Mouse Arthritis Model,”Immunopharmacology 10: 51-60, 1985.
Reiter and Pongó, “On Triazoles. VI [1]. The Acylation of 5-Amino-1,2,4-triazoles,” J.Heterocyclic Chem. 24: 127-142, Jan.-Feb. 1987.
Sarayba et al., “Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-γ ligand,”Experimental Eye Research 80: 435-442, 2005.
Sheets et al., “Cataract- and Lens-Specific Upregulation of ARK Receptor Tyrosine Kinase in Emory Mouse Cataract,”Investigative Ophthalmology&Visual Science 43(6): 1870-1875, Jun. 2002.
Smith et al., “Oxygen-Induced Retinopathy in the Mouse,”Investigative Ophthalmology&Visual Science 35(1): 101-111, Jan. 1994.
Somigliana et al., “Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis,”Human Reproduction 14(12): 2944-2950, 1999.
Suzuki et al., “Simple Synthesis of Ring-Fused Pyridazin-3-Ones,”Heterocycles 57(4): 723-731, 2002.
Von Der Thüsen et al., “Adenoviral Transfer of Endothelial Nitric Oxide Synthase Attenuates Lesion Formation in a Novel Murine Model of Postangioplasty Restenosis,”Arterioscler. Thromb. Vasc. Biol. 24:357-362, Feb. 2004.
Wronski et al., “Endocrine and Pharmacological Suppressors of Bone Turnover Protect against Osteopenia in Ovariectomized Rats,”Endocrinology 125(2): 810-816, 1989.
Xu et al., “Requirement for the tyrosine kinase Axl in angiogenesis and tumor growth,”Proc. Amer. Assoc. Cancer Res. 46, 2005. Tumor Biology 14: Signaling and Angiogenesis; Abstract #2019 of observations disclosed at American Association Cancer Research General Meeting, Apr. 16-20, 2005, Anaheim, California, 1 page.
Yin et al., “Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection,”Transplantation 73(4): 657-660, Feb. 27, 2002.
Singh et al., U.S. Appl. No. 11/967,163, filed Dec. 29, 2007, entitled Polycyclic Aryl Substituted Triazoles and Polycyclic Heteroaryl Substituted Triazoles Useful As Axl Inhibitors.
Modest et al., “2,4-Diaminopyrimidines from Dicyandiamide. III. Reaction with Monocyclic Ketones,”J. Org. Chem. 30(6): 1837-1840, Jun. 1965.
Sigma-Aldrich Co. Catalog entitled “Aldrich Advancing Science,” pp. 739, 752 and 761, 2005.
Ding Pingu
Goff Dane
Heckrodt Thilo J.
Holland Sacha
Litvak Joane
Chu Yong
Rigel Pharmaceuticals Inc.
Seed IP Law Group PLLC
LandOfFree
Bicyclic aryl and bicyclic heteroaryl substituted triazoles... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic aryl and bicyclic heteroaryl substituted triazoles..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic aryl and bicyclic heteroaryl substituted triazoles... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2660271